Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 387-390

  Mück Seler, Dorotea ^a   Sagud, Marina ^b   Mihaljevi Peles, Alma ^b   Jakovljevi, Miro ^b   Pivac, Nela ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPIN 2 ONE DERIVATIVE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PAROXETINE; TIANEPTINE; TRIACYLGLYCEROL;

ADULT; ANAMNESIS; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; LETTER; LIPID BLOOD LEVEL; MAJOR DEPRESSION; MENOPAUSE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEMI STRUCTURED INTERVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHOLESTEROL; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MIDDLE AGED; PAROXETINE; THIAZEPINES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 79955636628     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318218f45f     Document Type: Letter

References (15)

1. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signaling. Nat Rev Neurosci. 2007;8:128-140. (Pubitemid 46146951)
2. Jow G-M, Yang T-T, Chen C-L. Leptin and cholesterol levels are low in major depressive disorder, bur high in schizophrenia. J Affect Disord. 2006;90:21-27. (Pubitemid 43005033)
3. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Platelet serotonin and lipid levels in psychotic mania. J Affect Disord. 2007; 9:247-251. (Pubitemid 44937419)
4. Oxenkrug GF, Branconnier RJ, Harto-Truax NJ, et al. Is serum cholesterol a biological marker for major depressive disorder? Am J Psychiatry. 1983;140:920-921. (Pubitemid 13061002)
5. Sagud M, Mihaljevic-Peles A, Pivac N, et al. Lipid levels in female patients with affective disorders. Psychiatry Res. 2009;168:218-221.
6. Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002;43:310-316.
7. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol. 2003;23:155-168. (Pubitemid 36368793)
8. Muck-Seler D, Pivac N, Sagud M, et al. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1235-1243. (Pubitemid 35341573)
9. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical efficacy from in vitro potencies. J Clin Psychiatry. 2001;62(suppl 2):16-23. (Pubitemid 32578703)
10. McEwen BS, Chattaji S, Dimond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry. 2010;15:237-249.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
12. Papakostas GI, Ongur D, Iosifescu DV, et al. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004;14:135-142. (Pubitemid 38175431)
13. Bella R, Pennisi G, Cantone M, et al. Presentation and outcome of geriatric depression in subcortical ischemic vascular disease. Gerontology. 2010;56:298-302.
14. Muldoon MF, Mackey RH, Korytkowski MT, et al. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab. 2006;91:718-721. (Pubitemid 43236948)
15. Kim EJ, Yu BH. Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol. 2005;25:597-599.